Literature DB >> 9987155

Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination.

S Stienlauf1, M Shoresh, A Solomon, T Lublin-Tennenbaum, Y Atsmon, Y Meirovich, E Katz.   

Abstract

Administration of vaccinia immune globulin (VIG), derived from vaccinated healthy adult volunteers, is the treatment-of-choice for patients suffering from severe complications following smallpox vaccination. The present study was aimed to determine the time interval after vaccination, at which the highest titer of neutralizing antibodies is obtained. Ninety-nine 18-year-old soldiers, immunized with vaccinia virus at birth, participated in the study, 87 of whom had detectable antibodies against vaccinia virus prior to re-vaccination. Their initial average neutralizing antibodies titer (NT50) was 27. Fourteen days after re-vaccination the titer reached 152 and then dropped to 136, 119, 110 and 87 at 21, 30, 45 and 60 d, respectively. The titers of vaccinia antibodies induced in vaccinees without detectable antibodies at the start of the study, were significantly lower and the titers observed after re-vaccination were: 62, 56, 66, 38 and 34, at 14, 21, 30, 45 and 60 d, respectively. In an additional study, 65 volunteers vaccinated at birth and again at the age of 8 years old were re-vaccinated. Fourteen days later their NT50 was higher than those vaccinated only at birth. It can be concluded that bleeding of vaccinees 14 d following re-vaccination is the preferable time for the preparation of VIG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9987155     DOI: 10.1016/s0264-410x(98)00197-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak.

Authors:  Kevin L Karem; Mary Reynolds; Zach Braden; Gin Lou; Nikeva Bernard; Joanne Patton; Inger K Damon
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

2.  Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Authors:  Antonio Cosma; Silja Bühler; Rashmi Nagaraj; Caroline Staib; Anna-Lena Hammarin; Britta Wahren; Frank D Goebel; Volker Erfle; Gerd Sutter
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

3.  Experimental infection of prairie dogs with monkeypox virus.

Authors:  Shu-Yuan Xiao; Elena Sbrana; Douglas M Watts; Marina Siirin; Amelia P A Travassos da Rosa; Robert B Tesh
Journal:  Emerg Infect Dis       Date:  2005-04       Impact factor: 6.883

4.  Serological Immunity to Smallpox in New South Wales, Australia.

Authors:  Valentina Costantino; Mallory J Trent; John S Sullivan; Mohana P Kunasekaran; Richard Gray; Raina MacIntyre
Journal:  Viruses       Date:  2020-05-18       Impact factor: 5.048

Review 5.  Mechanisms that determine plasma cell lifespan and the duration of humoral immunity.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

6.  Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax.

Authors:  Claire M Midgley; Mike M Putz; Jonathan N Weber; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

7.  Frequency of revaccination against smallpox.

Authors:  Samuel Baron; Jingzhi Pan; Joyce Poast
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.